Fernando Daniel García Ayala

Dr. Fernando Daniel García Ayala

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Fernando Daniel García AyalaFernando Daniel García Ayala
Fernando Daniel García Ayala
Maria de la Luz Ayala-MadrigalMaria de la Luz Ayala-Madrigal
Maria de la Luz Ayala-Madrigal
JPJorge Peregrina-Sandoval
Jorge Peregrina-Sandoval
JOJOSE MIGUEL MORENO ORTIZ
JOSE MIGUEL MORENO ORTIZ
AMAnahí González Mercado
Anahí González Mercado
Melva Gutierrez-AnguloMelva Gutierrez-Angulo
Melva Gutierrez-Angulo
Background/Objectives: Colorectal cancer (CRC) represents a major public health problem in Mexico and is among the malignancies with the highest morbidity and mortality. Alterations in TP53 are frequent molecular events in tumors with chromosomal instability; however, information on TP53 variants in the Mexican population, particularly in exons 4-8, remains limited. Exons 4-8 comprise the main coding region of the p53 DNA-binding domain; therefore, this study aimed to identify TP53 variants in these regions and evaluate p53 protein expression by immunohistochemistry in sporadic CRC. Methods: Tumor samples from 142 patients who underwent surgical resection without neoadjuvant treatment were analyzed. DNA was extracted from tumor tissue. TP53 exons 4-8 were amplified by polymerase chain reaction (PCR), and variants were identified by Sanger sequencing. p53 immunohistochemistry was performed in 40 tumors and 36 adjacent tissues, and nuclear expression was assessed using the Immunoreactivity Score. Results: Forty-three heterozygous variants were identified in 106/142 patients, representing 75% of the cohort. Thirty-one patients carried oncogenic variants, mainly clustered within the DNA-binding domain and involving hotspot residues such as Arg175, Tyr220, Gly245, Arg248, Arg273, and Arg282. Nuclear p53 expression was observed in 9/40 tumors, whereas all adjacent tissues were negative. Conclusions: TP53 alterations in exons 4-8 are frequent and heterogeneous in this Mexican cohort. Integrating mutational profiling with p53 immunohistochemistry provides complementary information for the biological interpretation of these tumors, including variants of translational interest.

Verified
Journal Article
Open access
PDF file
Fernando Daniel García AyalaFernando Daniel García Ayala
Fernando Daniel García Ayala
Maria de la Luz Ayala-MadrigalMaria de la Luz Ayala-Madrigal
Maria de la Luz Ayala-Madrigal
JPJorge Peregrina-Sandoval
Jorge Peregrina-Sandoval
JOJOSE MIGUEL MORENO ORTIZ
JOSE MIGUEL MORENO ORTIZ
AMAnahí González Mercado
Anahí González Mercado
Melva Gutierrez-AnguloMelva Gutierrez-Angulo
Melva Gutierrez-Angulo
The TP53 gene, frequently mutated across multiple cancer types, plays a pivotal role in regulating the cell cycle and apoptosis through its protein, p53. Missense variants of uncertain significance (VUSs) in TP53 present challenges in understanding their impact on protein function and complicate clinical interpretation. This study aims to analyze the effects of missense VUSs in p53, as reported in the gnomAD database, with a specific focus on their impact on protein stability and phosphorylation. In this study, 33 missense VUSs in TP53 reported in the gnomAD database were analyzed using in silico tools, including PhosphositePlus v6.7.4, the Kinase Library v0.0.11, and Dynamut2. Of these analyzed variants, five disrupted known phosphorylation sites, while another five created new consensus sequences for phosphorylation. Moreover, 20 variants exhibited a moderate destabilizing effect on the protein structure. At least three missense VUSs were identified as potentially affecting p53 function, which may contribute to cancer development. These findings highlight the importance of integrating in silico structural and functional analysis to assess the pathogenic potential of missense VUSs.